Please use this identifier to cite or link to this item:
https://doi.org/10.1182/blood-2010-01-265082
Title: | Cannabinoid receptor 2 and its agonists mediate hematopoiesis and hematopoietic stem and progenitor cell mobilization | Authors: | Jiang, S. Alberich-Jorda, M. Zagozdzon, R. Parmar, K. Fu, Y. Mauch, P. Banu, N. Makriyannis, A. Tenen, D.G. Avraham, S. Groopman, J.E. Avraham, H.K. |
Issue Date: | 20-Jan-2011 | Citation: | Jiang, S., Alberich-Jorda, M., Zagozdzon, R., Parmar, K., Fu, Y., Mauch, P., Banu, N., Makriyannis, A., Tenen, D.G., Avraham, S., Groopman, J.E., Avraham, H.K. (2011-01-20). Cannabinoid receptor 2 and its agonists mediate hematopoiesis and hematopoietic stem and progenitor cell mobilization. Blood 117 (3) : 827-838. ScholarBank@NUS Repository. https://doi.org/10.1182/blood-2010-01-265082 | Abstract: | Endocannabinoids are arachidonic acid derivatives and part of a novel bioactive lipid signaling system, along with their G-coupled cannabinoid receptors (CB1 and CB2) and the enzymes involved in their biosynthesis and degradation. However, their roles in hematopoiesis and hematopoietic stem and progenitor cell (HSPC) functions are not well characterized. Here, we show that bone marrow stromal cells express endocannabinoids (anandamide and 2-arachidonylglycerol), whereas CB2 receptors are expressed in human and murine HSPCs. On ligand stimulation with CB2 agonists, CB2 receptors induced chemotaxis, migration, and enhanced colony formation of bone marrow cells, which were mediated via ERK, PI3-kinase, and Gαi-Rac1 pathways. In vivo, the CB2 agonist AM1241 induced mobilization of murine HSPCs with short-and long-term repopulating abilities. In addition, granulocyte colony-stimulating factor -induced mobilization of HSPCs was significantly decreased by specific CB 2 antagonists and was impaired in Cnr2-/- cannabinoid type 2 receptor knockout mice. Taken together, these results demonstrate that the endocannabinoid system is involved in hematopoiesis and that CB 2/CB2 agonist axis mediates repopulation of hematopoiesis and mobilization of HSPCs. Thus, CB2 agonists may be therapeutically applied in clinical conditions, such as bone marrow transplantation. © 2011 by The American Society of Hematology. | Source Title: | Blood | URI: | http://scholarbank.nus.edu.sg/handle/10635/125367 | ISSN: | 00064971 | DOI: | 10.1182/blood-2010-01-265082 |
Appears in Collections: | Staff Publications |
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.